

A thick, blue, wavy horizontal line that spans across the top of the page, curving downwards in the center and upwards at the ends.

Hepatitis E Virus (HEV) and Blood Components:

Information for clinical and transfusion
laboratory staff

Introduction

- Hepatitis E Virus (HEV)
 - RNA virus
 - Four genotypes:
 - 1 + 2 are human viruses
 - 3 + 4 are animal viruses (transmitted zoonotically)
- Increase in the reported cases of HEV arising from infection acquired within the UK (i.e. 'non-travel associated')
- Cases of non-travel associated infection are most likely to be:
 - caused by the genotype 3 strain (associated with pigs)

Incidence of clinical acute HEV hepatitis in the UK

Year	Number of confirmed cases
2003	124
2004	149
2005	329
2006	289
2007	162
2008	176
2009	175
2010	274
2011	456
2012	578
2013	692
2014	869
2015	616 (Jan to Sept)

Data: Public Health England. *Hepatitis E: symptoms, transmission, treatment and prevention*.
Accessed online via: <https://www.gov.uk/government/publications/hepatitis-e-symptoms-transmission-prevention-treatment> on
8th February 2016

HEV infection

- Most cases are asymptomatic.
- Symptomatic cases present as an acute but mild transient illness requiring supportive management only
- Average incubation period is approximately 40 days
- Symptoms can last on average 1-4 weeks
 - mild non-specific illness (fatigue, fever, nausea/vomiting)
 - derangement in liver enzymes and jaundice

HEV infection

- Immunocompetent patients are usually able to clear the virus
- In immunosuppressed patients, such as those undergoing transplant, HEV is more difficult to clear
 - lead to chronic changes including chronic inflammation and potential to develop cirrhosis

HEV transmission

- HEV is passed via oral-faecal route (contaminated sewage) in developing countries
- In developed countries, transmission potentially linked to:
 - eating under-cooked pork and game, processed pork products and some shell fish
 - transmission via blood components and organ transplantation
 - also via SD treated FFP, but now prepared from HEV negative plasma.

Hepatitis E virus in blood components: a prevalence transmission study in southeast England (The Lancet, July 2014)

- Samples from blood donations given in the southeast of England from October 2012 – September 2013 were screened retrospectively for HEV RNA.
- Prevalence of HEV RNA in donations was **1 in 2848** (79 out of the 225,000 donations tested)
 - 54 of the 79 HEV RNA positive samples were genotyped: all were genotype 3.
- 129 blood components were manufactured from the 79 donations: 62 of these were transfused before identification of infected donation.
- Follow up of 43 recipients showed 18 (42%) had evidence of infection.
- HEV transmission via Red Cells, Platelets (pooled and apheresis), Fresh Frozen Plasma, and Granulocytes was identified.

Hepatitis E virus in blood components: a prevalence transmission study in southeast England (The Lancet, July 2014)

Conclusions

- HEV genotype 3 infections are widespread in the English population and in blood donors.
- Transfusion transmission linked to viral load/ serological status of donor.
- Transfusion-transmitted infection rarely caused acute morbidity.
- In some immunocompromised patients, infection became persistent, but could be influenced by reducing/ modifying immunosuppression or treating with Ribavirin.

SaBTO recommendations

- Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) set up a specific Hepatitis E working group in response to the Lancet article.

Key Recommendations:

- Introduce donor blood component testing to provide HEV negative blood components for patients undergoing solid organ or allogeneic stem cell transplants.
- Provide advice to allogeneic stem cell transplant and solid organ patients regarding risk of eating poorly-cooked pork or pork products including sausages and offal.

Indications for HEV negative blood components

- SaBTO expanded on the specific patient groups who should receive HEV negative blood components (see Box 1 on slide 15).
- Applies to cellular blood components (red cells, platelets and granulocytes) and plasma components (FFP and cryoprecipitate).
- No evidence at present to support a requirement for HEV negative blood components for pregnant women.

Testing and issue

- NHSBT now issues HEV negative blood components: all types of components are available as HEV negative.
- In 2016/17 a premium of £17.18 is being applied to each unit issued where HEV negative is requested as an additional requirement.
- Some components will be issued HEV negative as standard (see Box 2 on slide 16); the HEV premium does not apply to these components.
- NHSBT will provide HEV negative components for neonates and infants under the age of one year.

Component labelling

- Blood components manufactured by NHSBT that are HEV negative will be labelled 'NEG: HEV'



- Non-UK plasma components issued by NHSBT, i.e. MB FFP and MB Cryoprecipitate, are already tested and confirmed as HEV negative in the country of donation (Austria); these components do not identify this on the blood pack label.

Ordering and receipt

- A tick box has been added to OBOS to select HEV negative as an additional requirement for the component
 - this will be in addition to any requirement for the component to be irradiated or CMV negative.
- Components that have HEV negative as part of the mandatory requirements will be automatically provided as HEV negative (see Box 2 on slide 16), and there is no need to tick this box when ordering these components on OBOS.
- Methylene Blue (MB) treated frozen components are already screened for HEV during the manufacturing process; when ordering these components on OBOS, **DO NOT** tick the HEV negative box – if it is ticked our system will not allow for the component to be dispatched; the order will be cancelled and have to be re-ordered.
- HEV negative status of blood components has been added to EDN specification.

Transfusion laboratory

- No additional handling or storage requirements for HEV negative components.
- Patients who require HEV negative blood components may need to be flagged on your LIMS (see Box 1 on slide 15) – refer to local policy.
- Transfusion laboratory staff should be trained to recognise clinical details on transfusion request forms that may indicate the need for HEV negative blood components.
- Transfusion laboratory should inform any receiving referral hospitals of the need for HEV negative blood components for the patient.
- Any suspected HEV transmission by blood component transfusion should be reported to NHSBT as soon as possible.

BOX 1

Patients who require HEV negative components

- **Patients awaiting solid organ transplant (SOT)** – from 3 months prior to date of planned elective SOT or from the date of listing for a solid organ transplant.
- **Patients who have had SOT** – for as long as the patient is taking immunosuppressants.
- **Patients with acute leukaemia** – from diagnosis (unless/until decision made not to proceed with stem cell transplant).
- **Patients awaiting allogeneic stem cell transplant** – from 3 months prior to the date of planned transplant and up to 6 months following transplant, or for as long as the patient is immunosuppressed.
- **Extra corporeal procedures** – only included if within above indications.

BOX 2

Components issued HEV negative as standard

- Red cells for neonatal use (i.e. 'paedipack'/split pack)
- Platelets for neonatal use (i.e. 'paedipack'/split pack)
- Red cells for intrauterine transfusion
- Platelets for intrauterine transfusion
- Red cells for large volume transfusion
- Red cells, irradiated, for exchange transfusion (neonatal)
- Pooled granulocytes, irradiated

- Methylene blue fresh frozen plasma (paediatric)
- Methylene blue fresh frozen plasma (neonatal)
- Methylene blue cryoprecipitate (pooled)
- Methylene blue cryoprecipitate (single)